胸腔积液肺腺癌细胞中CXCR4、Ki67、MDM2、N-cadherin的表达及其与EGFR突变状态的关系

doi:10.3969/j.issn.1004-616x.2022.02.007

癌变·畸变·突变 ›› 2022, Vol. 34 ›› Issue (2): 114-118.doi: 10.3969/j.issn.1004-616x.2022.02.007

• 论著 • 上一篇

胸腔积液肺腺癌细胞中CXCR4、Ki67、MDM2、N-cadherin的表达及其与EGFR突变状态的关系

王蕊, 刘颖, 吴娟, 纪晓坤, 马阳, 郭晓, 杜芸

河北医科大学第四医院癌检中心, 河北石家庄 050011

收稿日期:2021-03-26 修回日期:2021-09-21 发布日期:2022-04-07
通讯作者: 杜芸,E-mail:18330186020@139.com E-mail:18330186020@139.com
作者简介:王蕊,E-mail:aijianzhongxin@163.com。
基金资助:
河北省财政厅政府资助专科能力建设和专科带头人培养项目(361006)

CXCR4, Ki67, MDM2 and N-cadherin expressions in lung adenocarcinoma pleural effusion cells and their correlation with EGFR mutation status

WANG Rui, LIU Ying, WU Juan, JI Xiaokun, MA Yang, GUO Xiao, DU Yun

Cancer Detection Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China)

Received:2021-03-26 Revised:2021-09-21 Published:2022-04-07

摘要/Abstract

摘要： 目的：研究胸腔积液肺腺癌细胞中趋化因子受体4(CXCR4)、增殖细胞核抗原Ki67、鼠双微体2(MDM2)和N-钙黏蛋白(Ncadherin)的表达与表皮生长因子受体(EGFR)突变状态的相关性。方法：收集46例晚期肺腺癌患者的胸腔积液，采用HE染色联合免疫细胞化学染色(ICC)法检测胸腔积液中是否含肿瘤细胞，突变扩增系统(ARMS)检测胸腔积液中癌细胞的EGFR基因突变状态，将癌细胞分为EGFR-TKI敏感突变组和EGFR野生型组。采用ICC法检测胸腔积液中肺腺癌细胞CXCR4、Ki67、MDM2和Ncadherin的表达，分析这些蛋白的表达阳性率和EGFR突变状态的相关性。结果：46例肺腺癌患者的恶性胸腔积液细胞中，31例(67.4%)存在EGFR-TKI敏感突变。CXCR4、Ki67、MDM2、N-cadherin表达阳性率与EGFR突变状态相关(r分别为0.452、0.428、0.417、0.524，均为P<0.05)，且EGFR-TKI敏感突变组细胞CXCR4、Ki67、MDM2、N-cadherin表达的阳性率明显高于EGFR野生型组(P<0.05)。结论：EGFR突变状态与CXCR4、Ki67、MDM2和N-cadherin的表达相关，EGFR突变状态下，胸腔积液肺腺癌细胞的CXCR4、Ki67、MDM2和N-cadherin的表达阳性率高于非突变状态下的表达阳性率。

关键词: 胸腔积液, 表皮生长因子受体, 趋化因子受体4, 细胞增殖核抗原Ki67, 鼠双微体2, N-钙黏蛋白

Abstract: OBJECTIVE： To explore correlations between EGFR mutation status and expressions of CXCR4， Ki67， MDM2 and N-cadherin in lung adenocarcinoma cells from pleural effusion. METHODS： Tumor cells from pleural effusions of lung adenocarcinomas were diagnosed using HE staining and immunocytochemistry (ICC). EGFR gene mutation status of lung adenocarcinoma patients was detected by the amplification refractory mutation system (ARMS) method，and divided into EGFR-TKI sensitive mutation group and EGFR wild- type group. Expressions of CXCR4，Ki67，MDM2 and N- cadherin were detected using the ICC technique，and the correlations between the expression levels of these proteins and EGFR mutation status were analyzed. RESULTS：In 46 patients with malignant pleural effusion，31 patients (67.4%) harbored EGFRTKI-sensitive mutations. The expression levels of CXCR4，Ki67，MDM2，and N-cadherin were correlated with EGFR mutation status (r=0.452， 0.428， 0.417， 0.524， respectively， P<0.05). CONCLUSION： Expression levels of CXCR4， Ki67， MDM2 and N-cadherin were correlated with EGFR mutation status. Furthermore， expression levels of CXCR4，Ki67，MDM2 and N-cadherin in lung adenocarcinoma cells with pleural effusions were higher in tumors with EGFR mutation than without mutation.

Key words: pleural effusion, EGFR, CXCR4, Ki67, MDM2, N-cadherin

中图分类号:

R734.2

王蕊, 刘颖, 吴娟, 纪晓坤, 马阳, 郭晓, 杜芸. 胸腔积液肺腺癌细胞中CXCR4、Ki67、MDM2、N-cadherin的表达及其与EGFR突变状态的关系[J]. 癌变·畸变·突变, 2022, 34(2): 114-118.

WANG Rui, LIU Ying, WU Juan, JI Xiaokun, MA Yang, GUO Xiao, DU Yun. CXCR4, Ki67, MDM2 and N-cadherin expressions in lung adenocarcinoma pleural effusion cells and their correlation with EGFR mutation status[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 114-118.

参考文献

[1] TANG E R, SCHREINER A M, PUA B B. Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS) [J]. J Thorac Dis, 2014, 6(Sup 5): S489-S501.
[2] GU J, KAWAI H, NIE L, et al. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53[J]. J Biol Chem, 2002, 277(22): 19251-19254.
[3] JAVID J, MIR R, JULKA P K, et al. Association of p53 and mdm2 in the development and progression of non-small cell lung cancer[J]. Tumor Biol, 2015, 36(7): 5425-5432.
[4] LIU L, WU C, WANG Y, et al. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival[J]. J Thorac Oncol, 2011, 6(11): 1793-1800.
[5] STEMMLER M P. Cadherins in development and cancer[J]. Mol Biosyst, 2008, 4(8): 835-850.
[6] LIU C F, LIU S Y, MIN X Y, et al. The prognostic value of CXCR4 in ovarian cancer: a meta-analysis[J]. PLoS One, 2014, 9(3): e92629.
[7] ZENG Y, WANG X, YIN B, et al. Role of the stromal cell derived factor-1/CXC chemokine receptor 4 axis in the invasion and metastasis of lung cancer and mechanism[J]. J Thorac Dis, 2017, 9(12): 4947-4959.
[8] GAO B, SUN Y H, ZHANG J H, et al. Spectrum of LKB1, EGFR, and KRAS mutations in Chinese lung adenocarcinomas [J]. J Thorac Oncol, 2010, 5(8): 1130-1135.
[9] NING H, LIU M, WANG L, et al. Clinicopathological features of Chinese lung cancer patients with epidermal growth factor receptor mutation[J]. J Thorac Dis, 2017, 9(3): 796-801.
[10] YOTSUKURA M, YASUDA H, SHIGENOBU T, et al. Clinical and pathological characteristics of EGFR mutation in operable early- stage lung adenocarcinoma[J]. Lung Cancer, 2017, 109: 45-51.
[11] NISHII T, YOKOSE T, MIYAGI Y, et al. Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancer[J]. BMC Cancer, 2014, 14: 610.
[12] SONOBE M, KOBAYASHI M, ISHIKAWA M, et al. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas[J]. Ann Surg Oncol, 2012, 19(Sup 3): S347-S354.
[13] MATSUMURA Y, OWADA Y, YAMAURA T, et al. Epidermal growth factor receptor gene mutation as risk factor for recurrence in patients with surgically resected lung adenocarcinoma: a matched-pair analysis[J]. Interact Cardiovasc Thorac Surg, 2016, 23(2): 216-222.
[14] TSAI M F, CHANG T H, WU S G, et al. EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway[J]. Sci Rep, 2015, 5: 13574.
[15] BI M M, SHANG B, WANG Z, et al. Expression of CXCR4 and VEGF- C is correlated with lymph node metastasis in non-small cell lung cancer[J]. Thorac Cancer, 2017, 8(6): 634-641.
[16] ZUO J, WEN M, LI S, et al. Overexpression of CXCR4 promotes invasion and migration of non-small cell lung cancer via EGFR and MMP-9[J]. Oncol Lett, 2017, 14(6): 7513-7521.
[17] ZHU W Y, HU X F, FANG K X, et al. Prognostic value of mutant p53, Ki-67, and TTF-1 and their correlation with EGFR mutation in patients with non-small cell lung cancer[J]. Histol Histopathol, 2019, 34(11): 1269-1278.
[18] WEN S, ZHOU W, LI C M, et al. Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: a meta- analysis of published studies involving 32 studies[J]. BMC Cancer, 2015, 15(1): 1-13.
[19] ENOKIDA Y, SHIMIZU K, ATSUMI J, et al. Prognostic potential of the MDM2309T>G polymorphism in stage I lung adenocarcinoma[J]. Cancer Med, 2016, 5(8): 1791-1801.
[20] LIU L, WU C, WANG Y, et al. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival[J]. J Thorac Oncol, 2011, 6(11): 1793-1800.
[21] BERGHMANS T, MASCAUX C, HALLER A, et al. EGFR, TTF-1 and Mdm2 expression in stage III non-small cell lung cancer: a positive association[J]. Lung Cancer, 2008, 62(1): 35- 44.
[22] NAKAGAWA M, BANDO Y, NAGAO T, et al. Expression of p53, Ki- 67, E- cadherin, N- cadherin and TOP2A in triple-negative breast cancer[J]. Anticancer Res, 2011, 31(6): 2389- 2393.
[23] BLASCHUK O W. N-cadherin antagonists as oncology therapeutics[J]. Philos Trans R Soc Lond B Biol Sci, 2015, 370(1661): 20140039.

胸腔积液肺腺癌细胞中CXCR4、Ki67、MDM2、N-cadherin的表达及其与EGFR突变状态的关系

CXCR4, Ki67, MDM2 and N-cadherin expressions in lung adenocarcinoma pleural effusion cells and their correlation with EGFR mutation status

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

编辑推荐

Metrics

本文评价

[1]	陈秀琼, 孟凡桥, 熊华, 周洋媚, 唐雯华, 邹燕梅. 转移性结直肠癌抗EGFR治疗的耐药机制研究进展[J]. 癌变·畸变·突变, 2020, 32(1): 67-71.
[2]	马阳, 吴娟, 纪晓坤, 王蕊, 杜芸, 王珩, 郭晓, 张艳. 沉默表皮生长因子受体的表达对肺腺癌A549细胞自噬的影响[J]. 癌变·畸变·突变, 2019, 31(5): 347-351,358.
[3]	郭晓, 王蕊, 吴娟, 纪晓坤, 王珩, 张艳, 马阳, 杜芸. 肺腺癌患者新鲜细胞学标本EGFR基因突变检测及意义[J]. 癌变·畸变·突变, 2018, 30(1): 67-70.
[4]	邓燕霞, 古盼, 刘海龙, 郑凯, 刘建军, 黄新凤, 李习艺, 黄海燕. 苯并芘诱导肝脏的炎症损伤及EGFR的表达变化[J]. 癌变·畸变·突变, 2017, 29(5): 383-386.
[5]	金华，马翔宇，郭霞，刘艳，张洁，古扎丽努尔·阿不力孜. HER-2、MMP-2、IGF-1和VEGF在宫颈癌组织中的表达及意义[J]. 癌变·畸变·突变, 2014, 26(6): 446-448.
[6]	周小琼，邓小玲，傅玉才，许铭炎. TGF-β及EGF信号对溶血磷脂酸诱导口腔鳞癌细胞增殖的影响[J]. 癌变·畸变·突变, 2014, 26(1): 6-9.
[7]	王为民, 高永生. N-甲基-N'-硝基-N-亚硝胍抑制细胞表皮生长因子受体酪氨酸激酶活性[J]. , 2011, 23(4): 275-278.
[8]	由　田, 刘　政, 邱广斌, . 高分辨率熔解曲线分析技术在检测非小细胞肺癌组织EGFR基因突变中的应用[J]. 癌变·畸变·突变, 2010, 22(6): 444-447.
[9]	熊术道李景荣温博贵李冠武李　璟. 人膀胱移行细胞癌EGFR基因片段与核基质蛋白的相关性[J]. 癌变·畸变·突变, 2007, 19(2): 106-109.